Over-Optimistic Portrayal of Life-Supporting Treatments in Newspapers and Internet
By Thaddeus Pope,
Medical Futility Blog
| 08. 09. 2014
Several Taiwanese researchers have
just published a new study: "Over-Optimistic Portrayal of Life-Supporting Treatments in Newspapers and on the Internet: A Cross-Sectional Study Using Extra-Corporeal Membrane Oxygenation as an Example."
From the article's conclusion: Newspapers and the Internet have the potential to influence patients' knowledge and attitudes toward medical decision-making by providing over-optimistic medical information through the following ways:
- First, the mass media tend to attract the public’s attention by reporting the positive outcome of an important breakthrough in clinical medicine
- Second, the mass media tend to report patients who survive to hospital discharge, rather than those who die during hospital stay
- Third, the survived patients and their stories are more likely to be duplicated in newspapers and on Internet web pages than those who die during hospital stay.
Newspaper readers and Internet users may, therefore, mistakenly believe that ECMO can usually rescue patients from all life-threatening conditions. However, ECMO, similar to other aggressive LST such as CPR, is ethically appropriate to be initiated on patients with
reversible diseases, not on those with irreversible diseases.
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...